Predictors of long-term remission in patients with Graves' disease: A single center experience

Endocrine

Volumn 44, Issue 2, 2013, Pages 448-453

  Anagnostis, Panagiotis ^a   Adamidou, Fotini ^a   Polyzos, Stergios A ^b   Katergari, Simoni ^a   Karathanasi, Eleni ^a   Zouli, Chrisanthi ^a   Panagiotou, Athanasios ^a   Kita, Marina ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Antithyroid drugs; Graves' disease; Orbitopathy; Predictors of remission

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; LEVOTHYROXINE; LIOTHYRONINE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THYROTROPIN; THYROXINE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; ENDOCRINE OPHTHALMOPATHY; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; GREECE; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SMOKING; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84885619893     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9895-0     Document Type: Article

References (36)

1. G.A. Brent, Graves' disease. N. Engl. J. Med. 358, 2594-2605 (2008)
2. M. Schott, W.A. Scherbaum, N.G. Morgenthaler, Thyrotropin receptor autoantibodies in Graves' disease. Trends Endocrinol. Metab. 16, 243-248 (2005)
3. A.J. Hedley, R.E. Young, S.J. Jones, W.D. Alexander, P.D. Bewsher, Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin. Endocrinol. (Oxf) 31, 209-218 (1989)
4. D. Cooper, Antithyroid drugs. N. Engl. J. Med. 352, 905-917 (2005)
5. P. Abraham, A. Avenell, C.M. Park, W.A. Watson, J.S. Bevan, A systematic review of drug therapy for Graves' hyperthyroidism. Eur. J. Endocrinol. 153, 489-498 (2005)
6. R.S. Bahn, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association, American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 17, 456-520 (2011)
7. N.S. Glaser, D.M. Styne, Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 121, e481-e488 (2008)
8. F. Kaguelidou, C. Alberti, M. Castanet, M.A. Guitteny, P. Czernichow, J. Léger, French Childhood Graves' Disease Study Group, Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J. Clin. Endocrinol. Metab. 93, 3817-3826 (2008)
9. A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn, Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 85, 1038-1042 (2000)
10. H. Schleusener, J. Schwander, C. Fischer, R. Holle, G. Holl, K. Badenhoop, J. Hensen, R. Finke, U. Bogner, W.R. Mayr et al., Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol. (Copenh) 120, 689-701 (1989)
11. C. Cappelli, E. Gandossi, M. Castellano, C. Pizzocaro, B. Agosti, A. Delbarba, I. Pirola, E. De Martino, E.A. Rosei, Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocr. J. 54, 713-720 (2007)
12. C. Carella, G. Mazziotti, F. Sorvillo, M. Piscopo, M. Cioffi, P. Pilla, R. Nersita, S. Iorio, G. Amato, L.E. Braverman, E. Roti, Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16, 295-302 (2006)
13. T. Yasuda, Y. Okamoto, N. Hamada, K. Miyashita, M. Takahara, F. Sakamoto, T. Miyatsuka, T. Kitamura, N. Katakami, D. Kawamori, M. Otsuki, T.A. Matsuoka, H. Kaneto, I. Shimomura, Serum vitamin D levels are decreased in patients without remission of Graves' disease. Endocrine 43(1), 230-232 (2012)
14. M. Feng, H. Li, S.F. Chen, W.F. Li, F.B. Zhang, Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid diseases: a meta-analysis. Endocrine, (2012). doi: 10.1007/s12020-012-9812-y
15. H. Allannic, R. Fauchet, J. Orgiazzi, A.M. Madec, B. Genetet, Y. Lorcy, A.M. Le Guerrier, C. Delambre, V. Derennes, Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J. Clin. Endocrinol. Metab. 70, 675-679 (1990)
16. A.P. Weetman, A.P. Pickerill, P. Watson, V.K. Chatterjee, O.M. Edwards, Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. QJM 87, 337-341 (1994)
17. R.V.P.C. Garcia-Mayor, R. Luna-Cano, L.F. Perez-Mendez, J.C. Galofre, A. Andrade, Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J. Endocrinol. Invest. 15, 815-820 (1992)
18. D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J.Y. Herry, H. Allannic, Antithyroid drugs and Graves' disease-prospective randomized assessment of long-term treatment. Clin. Endocrinol. (Oxf) 50, 127-132 (1999)
19. T. Wille, B. Müller, D. Noth, U. Bürgi, P. Diem, Long-term follow up after antithyroid drug treatment in Graves' disease. Praxis (Bern 1994) 95, 1121-1127 (2006)
20. T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58, 95-100 (2011)
21. S.R. Page, C.E. Sheard, M. Herbert, M. Hopton, W.J. Jeffcoate, A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin. Endocrinol. (Oxf) 45, 511-516 (1996)
22. Y.K. Choo, W.S. Yoo, D.W. Kim, H.K. Chung, Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease. Thyroid 20, 949-954 (2010)
23. D. Glinoer, P. de Nayer, M. Bex, Belgian Collaborative Study Group on Graves' Disease, Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur. J. Endocrinol. 144, 475-483 (2001)
24. F. Bolaños, M. González-Ortiz, H. Durón, C. Sánchez, Remission of Graves' hyperthyroidism treated with methimazole. Rev. Invest. Clin. 54, 307-310 (2002)
25. K. Hashizume, K. Ichikawa, A. Sakurai, S. Suzuki, T. Takeda, M. Kobayashi, T. Miyamoto, M. Arai, T. Nagasawa, Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. 324, 947-953 (1991)
26. S.K. Grebe, C.M. Feek, H.C. Ford, J.N. Fagerström, D.P. Cordwell, J.W. Delahunt, R.J. Toomath, A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin. Endocrinol. (Oxf) 48, 585-592 (1998)
27. G. Benker, D. Reinwein, G. Kahaly, L. Tegler, W.D. Alexander, J. Fassbinder, H. Hirche, Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin. Endocrinol. (Oxf) 49, 451-457 (1998)
28. H. Sato, M. Minagawa, N. Sasaki, S. Sugihara, I. Kazukawa, K. Minamitani, K. Wataki, S. Konda, H. Inomata, K. Sanayama, Y. Kohno, Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome. J. Pediatr. Endocrinol. Metab. 24, 257-263 (2011)
29. T. Yamada, T. Aizawa, Y. Koizumi, I. Komiya, K. Ichikawa, K. Hashizume, Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves' disease. J. Am. Geriatr. Soc. 42, 513-516 (1994)
30. P. Vitti, T. Rago, L. Chiovato, S. Pallini, F. Santini, E. Fiore, R. Rocchi, E. Martino, A. Pinchera, Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7, 369-375 (1997)
31. H. Cinemre, C. Bilir, F. Gokosmanoglu, N. Akdemir, B. Erdogmus, R. Buyukkaya, Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil. Clin. Invest. Med. 32, E199-E205 (2009)
32. Ρ. Prakash, Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99 m thyroid uptake and TSH concentrations as prognostic indicators. Eur. J. Nucl. Med. 23, 118-122 (1996)
33. B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, Basedow Study Group, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 15, 1047-1054 (2005)
34. W.E. Wood, Role of TSH measurements in predicting the outcome of treatment for Graves' disease following drug therapy. Postgrad. Med. J. 71, 222-223 (1995)
35. J.N. Talbot, F. Duron, R. Féron, P. Aubert, G. Milhaud, Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year. J. Endocrinol. Invest. 12, 589-595 (1989)
36. O. Ishtiaq, S. Waseem, M.N. Haque, N. Islam, A. Jabbar, Remission of Grave's disease after oral anti-thyroid drug treatment. J. Coll. Physicians Surg. Pak. 19, 690-693 (2009)